Korea Ratings Downgrades Daol Investment Securities' Credit Rating
Kim SangJin
letyou@alphabiz.co.kr | 2024-10-23 07:41:36
Photo = Daol Investment & Securities
[Alpha Biz= Reporter Kim Sangjin] Korea Ratings announced on October 22 that it has downgraded Daol Investment Securities' corporate credit rating from A (negative) to A- (stable). The credit ratings for the company's commercial paper and electronic short-term bonds were also lowered from A2 to A2-.
The downgrade was attributed primarily to a decline in market share and profitability for Daol Investment Securities. The company's operating net profit decreased from 202.2 billion KRW in 2022 to 160.8 billion KRW in 2023, with only 60.3 billion KRW reported in the first half of this year. During the same period, its market share fell from 1.1% to 0.8%, and then to 0.5%.
Korea Ratings stated, "Daol Investment Securities is strengthening its sales and trading (S&T), bond management, and corporate finance to expand its revenue base. However, it is expected to be difficult to improve market dominance in the short term."
Additionally, Korea Ratings evaluated that the capital adequacy and soundness indicators of Daol Investment Securities have also deteriorated, significantly impacted by the sluggish real estate market. The burden of real estate project financing (PF) continues to be a concern. As of the end of June this year, Daol Investment Securities' real estate PF exposure amounted to 445.3 billion KRW, accounting for 62.3% of its equity capital.
[ⓒ AlphaBIZ. 무단전재-재배포 금지]
많이 본 기사
- 1AMD’s Lisa Su Forges Broad Semiconductor Alliance with Samsung Electronics and Naver in Korea
- 2Trial to Begin in NPS Lawsuit Against Samsung Over 2015 Merger
- 3Kyobo Life Enters Savings Bank Sector After Securing Approval to Acquire SBI Savings Bank
- 4SEC Reclassifies Major Cryptocurrencies as Digital Commodities, Signaling Regulatory Shift
- 5LPG Shortage Deepens in India Amid Hormuz Disruption, Triggering Theft and Cooking Fuel Shift
- 6Korea Exchange Pledges Process Overhaul and Accountability After SCM Life Science Listing Error